AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03134222
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 200 mg tablets administered orally once daily with or without food
Trial: NCT03134222
Drug: Filgotinib placebo
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally once daily with or without food
Trial: NCT00054704
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole
Trial: NCT00654914
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
Trial: NCT02089997
Drug: Sodium Risedronate
RxNorm normalized name: Sodium risedronate hydrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium risedronate tablets
Trial: NCT00758836
Drug: acetominophen
RxNorm normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00758836
Drug: telcagepant
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00592930
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flexibly dosed oral olanzapine 2.5 to 15 mg/day
Trial: NCT01077596
Drug: Regular bupropion use
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Trial: NCT01077596
Drug: Regular SSRI (Selective serotonin reuptake inhibitors) use
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Trial: NCT01880593
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
Trial: NCT01880593
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02911597
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
Trial: NCT00135941
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
Trial: NCT00135941
Drug: insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
Trial: NCT00819741
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
Trial: NCT00819741
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
Trial: NCT00819741
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
Trial: NCT01161615
Drug: MRX-7EAT
RxNorm normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of up to two patches for up to 7 days.
Trial: NCT00418457
Drug: General anesthesia and opioids
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: General anesthesia, usually with sevoflurane, and opioid analgesia
Trial: NCT00418457
Drug: Regional analgesia and propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
Trial: NCT01313780
Drug: Oxycodone/Naloxone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose and administration : Upto 40mg B.I.D per daily.
Trial: NCT01313780
Drug: Oxycodone(single compound)
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose and administration : Upto 40mg B.I.D per daily.
Trial: NCT00679640
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04003350
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
Trial: NCT04003350
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
Trial: NCT04003350
Drug: Tylenol
RxNorm normalized name: Tylenol
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tylenol 1000 mg: take as needed every 8 hours
Trial: NCT04003350
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: •Gabapentin 200 mg with morning and evening Tylenol dose
Trial: NCT04003350
Drug: Metaxalone
RxNorm normalized name: Metaxalone
DrugBank: Metaxalone (DB00660)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metaxalone 800mg TID
Trial: NCT04003350
Drug: Esomeprazole 20mg
RxNorm normalized name: ESOMEPRAZOLE 20MG (BASE) CAP,EC
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg daily
Trial: NCT00883662
Drug: Levonorgestrel (Mirena, BAY86-5028)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
Trial: NCT00007839
Drug: beta alethine
RxNorm normalized name: Beta alethine
DrugBank: Alethine (DB05800)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289963
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Trial: NCT01820208
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
Trial: NCT00549718
Drug: Lurasidone HCl
RxNorm normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily
Trial: NCT01086254
Drug: Iniparib
RxNorm normalized name: Iniparib
DrugBank: Iniparib (DB13877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion
Trial: NCT01086254
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion
Trial: NCT01086254
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard
Trial: NCT04282954
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg, QD
Trial: NCT04282954
Drug: Esomeprazole placebo
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole placebo, QD
Trial: NCT00816595
Drug: pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01688934
Drug: V116517 50-mg tablets
RxNorm normalized name: V116517
DrugBank: V116517 (DB16060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally twice daily
Trial: NCT01688934
Drug: V116517 30-mg tablets
RxNorm normalized name: V116517
DrugBank: V116517 (DB16060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally twice daily
Trial: NCT03555929
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
Trial: NCT00317512
Drug: Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)
RxNorm normalized name: Hemoglobin-based oxygen carrier 201 is purified, glutaraldehyde-polymerized, bovine hemoglobin, mw 250000
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00317512
Drug: Voluven
RxNorm normalized name: Voluven
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00934492
Drug: Cotrimoxazole dispersible tablet
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
Trial: NCT00043901
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00552565
Drug: Rezular 15mg
RxNorm normalized name: sennosides, USP
DrugBank: Arverapamil (DB06669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets
Trial: NCT00552565
Drug: Rezular
DrugBank: Arverapamil (DB06669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezular 37.5mg 3xday up to 12 weeks
Trial: NCT00552565
Drug: Rezular
DrugBank: Arverapamil (DB06669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezular 75mg 3xday up to 12 weeks
Trial: NCT00002588
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002588
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00864006
Drug: Divalproex Sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00864006
Drug: Depakote DR Tablets
RxNorm normalized name: Depakote
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00977249
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00532116
Drug: EMSAM (Selegiline Transdermal System) 6mg
RxNorm normalized name: selegiline Transdermal System [Emsam]
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: STS 6mg/24hr
Trial: NCT00532116
Drug: EMSAM (Selegiline Transdermal System) 12mg
RxNorm normalized name: selegiline Transdermal System [Emsam]
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMSAm 12mg/24Hr
Trial: NCT01164488
Drug: danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated daily doses
Trial: NCT01164488
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated daily doses
Trial: NCT01164488
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Repeated daily doses
Trial: NCT02701296
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
Trial: NCT04092751
Drug: SCY-078 plus PRA
RxNorm normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
Trial: NCT00420303
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg injection once weekly
Trial: NCT01136382
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pMDI, inhalation, bid, 6 weeks
Trial: NCT00312039
Drug: Elvucitabine
RxNorm normalized name: Elvucitabine
DrugBank: Elvucitabine (DB06236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvucitabine 10 mg QD for 14days
Trial: NCT00006350
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00312039
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine 300 mg QD for 14 days
Trial: NCT00000310
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02639741
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
Trial: NCT01841502
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: paroxetine 20 mg once daily
Trial: NCT01841502
Drug: telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: telaprevir 1125 mg twice daily
Trial: NCT00319150
Drug: erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease dosage by 12.5% q 2 weeks according to an algorithm.
Trial: NCT00019708
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03349775
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
Trial: NCT03722342
Drug: TTAC-0001 and pembrolizumab combination
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)
Trial: NCT03416270
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
Trial: NCT04106882
Drug: Glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplement administered mid-scan.
Trial: NCT00382694
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00800709
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
Trial: NCT00667862
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02011971
Drug: Vinpocetine
RxNorm normalized name: Vinpocetine
DrugBank: Vinpocetine (DB12131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
Trial: NCT00262223
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
Trial: NCT01699360
Drug: Cyclosporine A, Tacrolimus, Sirolimus
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04271956
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
Trial: NCT04271956
Drug: Sonrotoclax
RxNorm normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po
Trial: NCT01892722
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration once weekly via i.m. injections.
Trial: NCT01892722
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.
Trial: NCT03977233
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
Trial: NCT03977233
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
Trial: NCT03977233
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
Trial: NCT00006350
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00739934
Drug: voriconazole (Vfend)
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Trial: NCT01845831
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.